Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Try Its Hand At Sunscreen Absorption Study, A MUsT For TEA Sponsors

Executive Summary

Agency may be teaming with an outside party to conduct a maximal usage trial on sunscreen formulations. FDA guidance advises MUsTs to assess systemic exposure to sunscreen drug ingredients, but ingredient sponsors have been loath to invest in such tests due to questions about cost and viability.

Advertisement

Related Content

Systemic Exposure Data A MUsT For OTC Monograph Sunscreens, Other Topical Drugs In FDA Draft Guidance
FDA’s MUsT Draft Guidance Extends Challenge To Wider OTC Drug Industry
FDA’s ‘Exploratory’ MUsT Won't Affect OTC Sunscreen Rulemaking Schedule
ICMAD Responds To Senate Proposal: Cosmetics Should Not Be Regulated Like Foods
Rep. Pallone Has Cosmetics Concerns, Possibly Coming To A Storefront Near You
GAO Report Casts Shade On Sunscreen Ingredients' Chances With FDA
FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review

Topics

Advertisement
UsernamePublicRestriction

Register

RS121515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel